Ziconotide Side Effects: Safety Signals and Warnings
Ziconotide safety concerns are compound-specific. The main listed side effects are Dizziness, Nausea, and Confusion and cognitive impairment. The main warning signals are Severe psychiatric symptoms (psychosis, suicidal ideation) - discontinue if these occur, Cognitive impairment may interfere with daily activities, and Meningitis risk due to intrathecal delivery device.
Direct Answer
Ziconotide (Prialt) is FDA-approved for severe chronic pain via intrathecal delivery - the only non-opioid intrathecal analgesic with regulatory approval. Phase 3 data demonstrates significant pain reduction in patients refractory to other analgesics including intrathecal opioids. Its N-type calcium channel mechanism is fully differentiated from opioid pathways. A highly specialized but validated analgesic for refractory chronic pain.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Cognitive & Nootropic
- Best for
- Severe chronic refractory pain (intrathecal), N-type calcium channel pharmacology, non-opioid analgesic research
Reported Side Effects
- Dizziness
- Nausea
- Confusion and cognitive impairment
- Nystagmus
- Hallucinations
- Gait disturbance
- Urinary retention
Warnings
- Severe psychiatric symptoms (psychosis, suicidal ideation) - discontinue if these occur
- Cognitive impairment may interfere with daily activities
- Meningitis risk due to intrathecal delivery device
- Elevated creatine kinase levels reported
- Not for epidural administration
Known or Plausible Interactions
- CNS depressants (additive sedation)
- Intrathecal opioids (can be used concomitantly but monitor closely)
- Antipsychotics (additive CNS effects)
- Anticoagulants (spinal hematoma risk with pump procedures)
Regulatory Context
FDA-approved (2004) for management of severe chronic pain in patients intolerant of or refractory to other therapies. Schedule V controlled substance. Marketed as Prialt by Jazz Pharmaceuticals.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Severe Chronic Pain Relief (Level A), Neuropsychiatric Side Effects (Level A), and Opioid-Sparing Effect (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Ziconotide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/ziconotide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.